Cardiol Therapeutics Inc.: Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19 Oakville, Ontario--(Newsfile Corp. - December 15, 2020) - Cardiol Therapeutics Inc. ( TSX: CRDL) ( Cardiol" or the " Company"), a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), announces that it has appointed contract research organization ("CRO") Worldwide Clinical Trials ("Worldwide"), as the Company initiates it's Phase II/III trial in high-risk patients hospitalized with COVID-19 at clinical centers throughout the United States. The double-blind, placebo-controlled clinical trial is designed to investigate the efficacy and safety of CardiolRx, a pharmaceutically produced extra strength cannabidiol formulation, in 422 hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. This patient population is at significant risk of developing cardiovascular complications, which are frequently fatal, during their illness.